CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
儿童 B 细胞急性淋巴细胞白血病的耐药机制
英文原题：Resistance Mechanisms in Pediatric B-Cell Acute Lymphoblastic Leukemia.
查看英文原题
Resistance Mechanisms in Pediatric B-Cell Acute Lymphoblastic Leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
尽管医学发展迅速，但即使在今天，急性淋巴细胞白血病（ALL）仍然是儿科临床医生面临的问题。现代医学已达到可治愈性的极限，尽管治愈率超过90%。约20%的接受治疗患者会出现复发，令人遗憾的是，10%的确诊ALL患者仍然无法治愈。在本文中，我们希望聚焦于B细胞白血病患者的治疗耐药和疾病复发，并将其置于ALL预后因素的背景下进行探讨。我们展示了类固醇治疗和Tyrosine Kinase Inhibitors耐药的机制，并评估遗传因素对治疗耐药的影响，尤其是TCF3::HLF易位。我们比较了治疗方案，并解读癌细胞如何对创新疗法——包括CAR-T 细胞疗法和单克隆抗体——产生耐药。我们文章中所作的比较有助于更深入地理解血液系统恶性肿瘤在ALL背景下的主要耐药因素。
展开英文摘要原文
Despite the rapid development of medicine, even nowadays, acute lymphoblastic leukemia (ALL) is still a problem for pediatric clinicians. Modern medicine has reached a limit of curability even though the recovery rate exceeds 90%. Relapse occurs in around 20% of treated patients and, regrettably, 10% of diagnosed ALL patients are still incurable. In this article, we would like to focus on the treatment resistance and disease relapse of patients with B-cell leukemia in the context of prognostic factors of ALL.
We demonstrate the mechanisms of the resistance to steroid therapy and Tyrosine Kinase Inhibitors and assess the impact of genetic factors on the treatment resistance, especially TCF3::HLF translocation.
We compare therapeutic protocols and decipher how cancer cells become resistant to innovative treatments-including CAR-T-cell therapies and monoclonal antibodies. The comparisons made in our article help to bring closer the main factors of resistance in hematologic malignancies in the context of ALL.
论文信息
- 作者
- Jędraszek K、Malczewska M、Parysek-Wójcik K、Lejman M
- 第一作者单位
- Student Scientific Society of Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland.Poland
- 通讯作者单位
- Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland.Poland
- 文献类型
- 综述
- 期刊
- International journal of molecular sciences2022 Mar 12
- 原文标识
- PubMed 35328487 · DOI 10.3390/ijms23063067
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →